sglt2 inhibitors vs glp 1 agonists Renal outcomes of and GLP1 in clinical practice Blood pressure effects of SGLT2

Combined anabolic and micronutrient vulnerabilities in these populations may influence musculoskeletal resilience

GLP-1s by year and indication GLP-1s by indication and year GLP-1 pipeline FAQs On March 19, 2026, the FDA approved a new, high-dose semaglutide (Wegovy HD) injection (7.2 mg) for once-weekly, subcutaneous (SC) administration for weight reduction and long-term maintenance

For men, at least 125 ounces

Pharmacological characterization of mono-, dual- and tri-peptidic agonists at GIP and GLP-1 receptors

Mechanisms of hepatic fibrogenesis

The distinction you made between the EVOKE trials (oral) and the liraglutide data (injectable) is a critical point for clinicians to understand